PPD and ERT will collaborate on all areas of the clinical development process to offer clients new efficiencies by aligning certain aspects of service delivery, including budget and proposal development, study startup, data management and invoicing.
“PPD and ERT plan to continue to employ the same types of data collection tools that each already uses in its day-to-day business, such as electronic clinical outcome assessment (eCOA) data collection solutions, centralized cardiac safety data collection solutions, and centralized spirometry data collection and respiratory solutions,” a PPD spokesman told Outsourcing-Pharma.com.
The partnership follows ERT’s decision in November to push into clinical trial management software with the purchase of eClinical Insights.
“ERT’s advanced technology in centralized cardiac safety, respiratory services and clinical outcome assessments (COA) complements PPD’s robust client offerings across our Phase I-IV clinical trials business,” said Paul Colvin, PPD’s EVP of clinical development. “ERT has an exemplary reputation in providing these services, and this partnership enhances PPD’s development capabilities across all therapeutic areas, with distinct advantages for respiratory, cardiovascular and late phase trials.”
The agreement with ERT helps PPD to expand its ability to provide resources for clients from early phase studies through regulatory approval. And PPD's operational expertise and global footprint offer ERT an opportunity to expand its reach and provide increased efficiencies in clinical trial deployment. Most recently PPD was signed up as a preferred partner by Sellas.
The companies plan to work together in such areas as proposals, contracting, invoicing, and study startup and execution. “PPD anticipates being able to use ERT’s solutions for patient safety and efficacy endpoint data collection to help clients conduct clinical trials in a more efficient and cost-effective manner,” a spokesman told us.
“ERT is proud to partner with PPD, a global leader in clinical development,” said Jim Corrigan, president and chief executive officer of ERT. “PPD and ERT share a common vision of transforming drug development through the power of technology and clinical services. The combined expertise, experience and commitment to client success of ERT and PPD will help drive industry innovation and the development of new therapies.”